Selective Internal Radiation Therapy (SIRT) for SDH-Deficient GIST demonstrates encouraging durable response rates: an international multicenter case series
Background/Objectives: Succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GISTs) are a rare subgroup of GISTs and respond poorly to conventional systemic therapies. This study describes long-term outcomes after yttrium-90 (Y-90) selective internal radiation therapy (SIRT) for p...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Langue: | anglais |
| Publié: |
20 August 2026
|
| In: |
Cancers
Year: 2026, Volume: 18, Numéro: 16, Pages: 1-12 |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers18162704 |
| Accès en ligne: | Verlag, kostenfrei, Volltext: https://doi.org/10.3390/cancers18162704 Verlag, kostenfrei, Volltext: https://www.mdpi.com/2072-6694/18/16/2704 
|
| Notes sur l'auteur: | Zachary T. Berman, Peter Hohenberger, Ramesh Bulusu, Steven C. Rose, Paul T. Fanta, Jonathan Evans, Steffen Diehl, Franka Menge, Nasim Ali and Jason K. Sicklick |
| Résumé: | Background/Objectives: Succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GISTs) are a rare subgroup of GISTs and respond poorly to conventional systemic therapies. This study describes long-term outcomes after yttrium-90 (Y-90) selective internal radiation therapy (SIRT) for progression of unresectable SDH-deficient GIST hepatic metastases. Methods: We performed a retrospective review of consecutive patients treated with SIRT at three tertiary referral centers in Europe and the United States. Data collection included demographics, tumor profiling, prior therapies, Y-90 dosimetry approach, imaging response, adverse events, and long-term outcomes. Results: Twelve patients (66.7% female) with a median age of 27 years (range, 17-57 years) were included. One patient had a complete response (8.3%) and seven had partial responses (58.3%) by modified Response Evaluation Criteria in Solid Tumors. Four patients (33.3%) had tumor shrinkage that did not meet partial response criteria. The objective response rate was 66.7%, with a disease control rate of 100%. One grade 3 or higher adverse event was observed (cholecystitis requiring cholecystectomy). At a median follow-up of 32 months (range, 3-77 months), two patients experienced disease progression. Median overall survival was not reached, with one death during follow-up. Conclusions: SIRT appears safe and effective for patients with progressive, unresectable SDH-deficient GIST hepatic metastases, with durable responses and limited serious toxicity. These findings suggest that SDH-deficient GIST may be more sensitive to radiation than previously appreciated and that SIRT may be a useful liver-directed approach for patients with limited systemic options. |
|---|---|
| Description: | Gesehen am 08.09.2026 |
| Description matérielle: | Online Resource |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers18162704 |